+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Myasthenia Gravis Treatment Market - Global Forecast 2026-2032- Product Image
Myasthenia Gravis Treatment Market - Global Forecast 2026-2032- Product Image
New

Myasthenia Gravis Treatment Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 192 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5674103
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The myasthenia gravis treatment market is experiencing significant structural change as innovative therapies, evolving care models, and new payer requirements prompt recalibration of strategies by healthcare organizations, manufacturers, and providers. Decision-makers must address shifting expectations and operational complexities to remain competitive and responsive in this expanding field.

Market Snapshot: Myasthenia Gravis Treatment Market

In 2025, the global myasthenia gravis treatment market was valued at USD 2.11 billion. The sector is forecast to reach USD 2.23 billion in 2026 and is projected to grow at a compound annual growth rate (CAGR) of 5.64%, ultimately achieving USD 3.10 billion by 2032. Market expansion is driven by accelerating adoption of innovative biologics, evolving practices in chronic disease management, and broader implementation of advanced clinical protocols across developed and emerging regions.

Scope & Segmentation of the Myasthenia Gravis Treatment Market

  • Therapeutic Classes: Includes acetylcholinesterase inhibitors, immunosuppressants—spanning corticosteroids and nonsteroidal agents—IV immunoglobulin, monoclonal antibodies targeting complement and B-cells, and plasma exchange therapies. Each class presents distinct mechanisms and is relevant across unique patient populations.
  • Administration Routes: Offers intravenous infusions, oral therapies, and subcutaneous self-administration solutions, each addressing specific clinical and logistical needs for both patients and healthcare providers.
  • Distribution Pathways: Comprises hospital pharmacies, retail pharmacy settings, and specialty online pharmacies. These access channels provide varied levels of patient support, adherence facilitation, and medication availability.
  • End-User Dynamics: Encompasses hospitals, outpatient clinics, and home care setups, coordinated by multidisciplinary teams to drive optimal management and compliance. These settings are critical for tailoring therapy to individual requirements and improving overall outcomes.
  • Regions Covered: Spans the Americas, Europe, Middle East and Africa, and Asia-Pacific. Each region features distinct regulatory, reimbursement, and clinical care environments influencing adoption rates and patient access to advanced treatments.
  • Technology and Service Partnerships: Industry collaborations span manufacturers, home-infusion service providers, and specialty distributors. Such partnerships are essential to enhancing patient access, expanding care delivery models, and supporting seamless logistics for novel treatments.

Key Takeaways for Senior Leaders

  • Targeted biologics are gaining traction, progressively altering clinical pathways and encouraging earlier use for specific patient groups. This trend demands continuous review of formulary strategies and treatment guidelines.
  • Regional disparities in healthcare infrastructure and payer models affect how quickly new therapies and administration modalities are adopted, making localized planning essential for effective commercial deployment.
  • Ensuring access to advanced therapies requires robust operational planning for infusion services, scalable self-administration options, and a resilient supply chain. This infrastructure forms the foundation of timely and equitable patient care.
  • Patient advocacy organizations and real-world evidence are playing a larger role in shaping clinical protocols and influencing coverage decisions, bringing patient-reported outcomes to the forefront of reimbursement negotiations.
  • Collaborative partnerships among manufacturers, distributors, and healthcare providers are key to successful market entry and widespread adoption of innovative medicines, particularly during complex product launches in multiple geographies.

Tariff Impact: Navigating Policy Complexity

Shifting United States tariff policies are materially affecting the cost base for pharmaceutical ingredients, finished biologics, and delivery devices in myasthenia gravis care. Manufacturers are revising procurement processes and exploring regional sourcing alternatives to mitigate risks and contain unexpected cost increases. Health systems and specialty pharmacies are adapting by reassessing contracts, optimizing inventory management, and diversifying supplier networks to ensure supply continuity. Pharmacy benefit managers and payers are updating reimbursement models to reflect tariff-related volatility. These combined efforts highlight the critical need for supply chain agility and proactive planning across the commercial ecosystem.

Methodology & Data Sources

The findings in this report are grounded in analysis of peer-reviewed clinical trials, regulatory filings, consensus treatment guidelines, and compiled real-world datasets. Insights are further validated by interviews with medical experts, pharmacy executives, and supply chain leaders, along with an examination of regional reimbursement and policy documents. Rigorous triangulation across multiple data streams ensures objective, robust, and actionable insights for decision-makers operating within the myasthenia gravis treatment market.

Why This Report Matters

  • Provides decision-focused guidance for aligning product development, clinical, and commercialization strategies in a landscape defined by rapid innovation and evolving payer expectations.
  • Supports senior leaders in anticipating supply chain volatility, navigating regulatory differences, and overcoming patient access challenges in varied markets.
  • Enables operational readiness and stakeholder collaboration necessary to optimize therapy rollout, manage infusion logistics, and engage advocacy networks more effectively.

Strategic Advantages for Decision-Makers

  • Enhances operational preparedness for deploying therapies, including options for infusion and at-home administration, supporting agility across care models.
  • Fosters productive engagement with payers, providers, and patient advocacy groups to accelerate adoption and maximize evidence-based outcomes.

Conclusion

Transformation of the myasthenia gravis treatment landscape requires coordinated effort, data-driven strategy, and partnership across all levels of the healthcare ecosystem. Integration of clinical advances and operational excellence positions stakeholders for sustainable leadership and robust patient outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Myasthenia Gravis Treatment Market, by Treatment Class
8.1. Acetylcholinesterase Inhibitors
8.2. Immunosuppressants
8.2.1. Corticosteroids
8.2.2. Nonsteroidal Immunosuppressants
8.2.2.1. Azathioprine
8.2.2.2. Cyclosporine
8.2.2.3. Mycophenolate Mofetil
8.3. Intravenous Immunoglobulin
8.4. Monoclonal Antibodies
8.4.1. Eculizumab
8.4.2. Ravulizumab
8.4.3. Rituximab
8.5. Plasma Exchange
9. Myasthenia Gravis Treatment Market, by Administration Route
9.1. Intravenous
9.2. Oral
9.3. Subcutaneous
10. Myasthenia Gravis Treatment Market, by Distribution Channel
10.1. Hospital Pharmacies
10.2. Online Pharmacies
10.3. Retail Pharmacies
11. Myasthenia Gravis Treatment Market, by End User
11.1. Clinics
11.2. Home Care
11.3. Hospitals
12. Myasthenia Gravis Treatment Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Myasthenia Gravis Treatment Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Myasthenia Gravis Treatment Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Myasthenia Gravis Treatment Market
16. China Myasthenia Gravis Treatment Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Alexion Pharmaceuticals, Inc.
17.6. Amgen Inc.
17.7. argenx SE
17.8. Biogen Inc.
17.9. CSL Limited
17.10. Fresenius Kabi AG
17.11. Grifols, S.A.
17.12. Horizon Therapeutics plc
17.13. Johnson & Johnson
17.14. Novartis AG
17.15. Pfizer Inc.
17.16. Regeneron Pharmaceuticals, Inc.
17.17. Roche Holding AG
17.18. Sandoz International GmbH
17.19. Sanofi S.A.
17.20. Takeda Pharmaceutical Company Limited
17.21. UCB S.A.
List of Figures
FIGURE 1. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CYCLOSPORINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CYCLOSPORINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ECULIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ECULIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 83. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 108. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 110. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 111. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 112. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 113. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 114. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 115. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 116. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 118. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 120. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 121. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 122. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 123. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 124. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 126. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 127. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 128. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 129. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 130. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 141. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 143. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 144. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 145. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 146. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 147. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 148. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 149. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 150. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 151. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 152. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 153. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 154. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 155. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 156. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 157. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 158. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 167. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 168. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 169. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 170. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 171. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 172. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 173. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 174. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 175. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 176. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 177. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 178. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 179. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 180. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 181. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 182. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 183. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 184. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 185. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 186. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 187. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 188. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 189. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 191. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 192. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 193. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 194. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 195. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 196. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 197. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 198. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 199. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 200. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 201. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 202. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 203. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 204. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 205. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Myasthenia Gravis Treatment market report include:
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • argenx SE
  • Biogen Inc.
  • CSL Limited
  • Fresenius Kabi AG
  • Grifols, S.A.
  • Horizon Therapeutics plc
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sandoz International GmbH
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • UCB S.A.

Table Information

Report AttributeDetails
No. of Pages192
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.23 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.1 Billion
Compound Annual Growth Rate5.6%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

Myasthenia Gravis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Myasthenia Gravis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 230 Pages
  • Global
From
Myasthenia Gravis Treatment Market Report 2025 - Product Image

Myasthenia Gravis Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Myasthenia Gravis Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Myasthenia Gravis Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 140 Pages
  • Global
From
Myasthenia Gravis Treatment - Global Strategic Business Report - Product Image

Myasthenia Gravis Treatment - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
Myasthenia Gravis Market - A Global and Regional Analysis: Focus on Drug Class and Regional Analysis - Analysis and Forecast, 2025-2035 - Product Image

Myasthenia Gravis Market - A Global and Regional Analysis: Focus on Drug Class and Regional Analysis - Analysis and Forecast, 2025-2035

  • Report
  • Global
From

About the Market

Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder that causes weakness in the skeletal muscles. MG is treated with a variety of drugs, including anticholinesterase drugs, immunosuppressants, and immunomodulators. Anticholinesterase drugs, such as pyridostigmine, are used to increase the availability of acetylcholine at the neuromuscular junction, thereby improving muscle strength. Immunosuppressants, such as azathioprine and cyclosporine, are used to reduce the production of antibodies that attack the neuromuscular junction. Immunomodulators, such as mycophenolate mofetil, are used to modulate the immune system and reduce the production of antibodies. The Myasthenia Gravis Drug market is a subset of the Central Nervous System Drugs market. It is composed of a variety of drugs used to treat MG, including anticholinesterase drugs, immunosuppressants, and immunomodulators. Companies in the Myasthenia Gravis Drug market include Merck, Pfizer, Novartis, GlaxoSmithKline, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.